Quercetin and allergy: what the research shows, and what it was done on
· by VEXTA Team
What the broadest synthesis actually covers
The question of whether quercetin is antihistaminic comes up constantly. Answering it requires looking at what the studies were done on.
Lv 2025 (Frontiers in Pharmacology, DOI 10.3389/fphar.2025.1673712) is the most complete synthesis available: a systematic review and meta-analysis conducted per PRISMA across PubMed, Web of Science and Embase, retaining thirteen eligible studies.
The title states its own scope: multi-target anti-allergic effects in animal models. This is preclinical research. It establishes mechanistic plausibility; it does not demonstrate an effect in humans.
The single human trial, and its decisive detail
Yamada 2022 (European Review for Medical and Pharmacological Sciences, PMID 35776034): a randomised, placebo-controlled, double-blind, parallel-group trial in 66 Japanese adults aged 22 to 78 with pollinosis, over four weeks.
Results: several scores on the Japanese Rhino-conjunctivitis Quality of Life Questionnaire improved significantly versus placebo — eye itching, sneezing, nasal discharge and sleep disturbance.
And here is the point almost nobody reports: the tested product was 200 mg of Quercetin Phytosome®, a formulation developed to raise bioavailability. That result does not transfer to standard quercetin aglycone, whose oral absorption is notoriously poor. The form matters at least as much as the dose.
It should also be noted that this trial appeared in a modest-tier journal and has not been replicated. It is a signal, not proof.
What to do with this, and what not to
What can be said: there is broad mechanistic plausibility in preclinical work, plus a single human trial, on one specific bioavailable form, at 200 mg for four weeks.
What must not be said: that quercetin treats allergy. Allergic rhinitis is managed medically, and allergen avoidance, antihistamines and specialist advice are not replaced by a supplement. If your symptoms disrupt sleep or work, the consultation comes first.
If you do test it, two markers from the trial: a form whose bioavailability is documented, and a four-week evaluation window — meaning during pollen season, not after it.